Autism & Schizophrenia Shared Risk and Your Genetics
By Scott Peeples | ExomeDNA Editorial Team | Reviewed: 2026-05-29
Disclaimer: This page contains general information only. For personal health decisions, consult a qualified clinician.
What is Autism & Schizophrenia Shared Risk?
Autism & Schizophrenia Shared Risk is a transdiagnostic genetic trait capturing the degree to which common genetic variants contribute simultaneously to autism spectrum disorder (ASD) and schizophrenia — two distinct neurodevelopmental and psychiatric conditions that share partially overlapping biological roots. Research confirms that SNP-based heritability for ASD and schizophrenia overlap at the genome-wide level, meaning some of the same upstream biological pathways influence susceptibility to both. Below, this page unpacks the science, the specific genes involved, and what this result means in a practical context.
The genetics behind Autism & Schizophrenia Shared Risk
The genetic architecture of ASD and schizophrenia is complex. Neither condition is caused by a single gene. Instead, hundreds to thousands of common variants each contribute a small amount of risk — and a meaningful subset of those variants appear to influence neurodevelopmental pathways relevant to both conditions. This is the core finding of transdiagnostic GWAS approaches: by studying ASD and schizophrenia together rather than separately, researchers can identify shared loci that conventional single-condition studies might miss or underpower.
Several genes in the authorized set for this trait illuminate distinct biological mechanisms:
ACTR1A encodes Arp1 (Actin-Related Protein 1A), the core subunit of the dynactin complex. Dynactin acts as an adapter between cytoplasmic dynein motor proteins and their cargo — including vesicles, organelles, and signaling molecules — enabling minus-end-directed transport along microtubules. In neurons, this retrograde axonal transport system is essential for synaptic vesicle recycling, clearing damaged proteins from axon terminals, and sustaining the health of distant synapses. Variants near ACTR1A may subtly impair this system, creating a form of neuronal vulnerability consistent with what is observed in both ASD and schizophrenia.
ACTR5 is a component of the INO80 and SWR1/SRCAP chromatin remodeling complexes, which regulate how DNA is packaged around histones. During critical windows of brain development, precise epigenetic programming shapes which genes are expressed in which cell types and at which times. Disruptions in chromatin remodeling machinery may alter gene expression programs in developing neurons and glia, with consequences that extend across diagnostic categories.
AGER — encoding the Receptor for Advanced Glycation End-products (RAGE) — is located in the Major Histocompatibility Complex (MHC) class III region on chromosome 6p21. This chromosomal region harbors some of the strongest known schizophrenia GWAS signals. RAGE activates NF-κB and MAPK inflammatory signaling cascades. Dysregulation of neuroinflammatory pathways during prenatal or early postnatal brain development has been implicated in both ASD and schizophrenia risk. AGER's position within this immunologically dense genomic neighborhood makes it a candidate of particular interest.
ABHD16A also resides in the 6p21 MHC region and is thought to be involved in phospholipid metabolism. Phospholipid composition of neuronal membranes influences receptor density, synaptic signaling, and membrane fluidity. Altered lipid metabolism is an emerging theme in the biology of neurodevelopmental conditions.
ABCF1 is an ABC transporter subfamily F member without transmembrane domains, with documented roles in translation regulation and immune function. It is expressed in lymphocytes and brain tissue — an expression profile that fits the emerging picture of immune-brain crosstalk in psychiatric risk.
ABCB9 localizes to lysosomes and is involved in peptide transport and lysosomal function. Lysosomal dysfunction has been linked to synaptic pruning abnormalities; dysregulated pruning is one mechanistic hypothesis for the synaptic over-connectivity observed in some ASD presentations.
ADAMTS7 and ADAMTSL3 are metalloprotease family members involved in extracellular matrix remodeling. The extracellular matrix scaffolds neuronal migration and synapse formation during development, and variants in ADAMTS-family genes have appeared in multiple psychiatric GWAS.
ABT1 functions as an activator of basal transcription — influencing the general transcriptional machinery that all genes rely on — making it a plausible contributor to broad neurodevelopmental gene expression programs.
Together, these genes point to at least four partially overlapping mechanisms: (1) retrograde axonal transport and synaptic maintenance, (2) chromatin remodeling and epigenetic gene regulation during brain development, (3) MHC-region neuroinflammatory signaling, and (4) extracellular matrix and lysosomal function. None of these pathways operates in isolation, and their convergence on a shared GWAS signal is consistent with the broader view that psychiatric conditions represent disruptions of interconnected neurodevelopmental systems.
What the research says
Research base: Moderate.
The primary evidence informing this trait comes from a large-scale meta-analysis conducted by the Autism Spectrum Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ASD), published in 2017 (PMID 28540026). This study analyzed data from over 16,000 individuals with autism spectrum disorder using a genome-wide association approach, identifying genetic loci that, in cross-disorder analyses with schizophrenia data, revealed shared genomic signals.
Over 16,000 individuals with ASD were included in the Psychiatric Genomics Consortium meta-analysis that identified the shared loci underlying this trait.[28540026]
The transdiagnostic finding is scientifically robust: multiple independent research programs — including the Cross-Disorder Group of the PGC — have documented statistically significant genetic correlations between ASD and schizophrenia. SNP-based heritability estimates for both conditions are substantial (ASD: ~65–80%; schizophrenia: ~60–80%), and a meaningful proportion of the genetic variance is shared.
ASD and schizophrenia share a positive genetic correlation in large-scale cross-disorder GWAS analyses, meaning common variants that increase risk for one tend, on average, to increase risk for the other — though the two conditions remain clinically and developmentally distinct.[28540026]
It is important to hold the scope of these findings accurately. The GWAS approach identifies statistical associations between common variants and diagnostic outcomes across populations. It does not tell any individual that they will develop either condition. For the vast majority of people, even those carrying all identified risk variants, neither ASD nor schizophrenia will manifest — the polygenic risk signal represents probabilistic population-level information, not a deterministic individual forecast.
The moderate confidence tier assigned to this trait reflects both the strength of the transdiagnostic GWAS finding and the inherent complexity of translating multi-condition psychiatric genetics into consumer-facing risk estimates. The biological mechanisms connecting individual gene candidates to clinical presentations are still being mapped.
How Autism & Schizophrenia Shared Risk affects you
Understanding that some of your genetic variants overlap with loci identified in ASD and schizophrenia research is not a prediction and is not equivalent to a clinical evaluation. ASD is typically identified in early childhood through behavioral and developmental assessment. Schizophrenia most commonly emerges in late adolescence or early adulthood. Both conditions are assessed clinically — not genetically — and both exist on spectrums of severity, presentation, and functional impact.
What this trait can meaningfully contribute to your understanding:
Family history context. Shared genetic architecture partly explains why first-degree relatives of individuals with ASD have elevated rates of schizophrenia spectrum features (and vice versa), and why both conditions tend to cluster in families. This genetic signal gives biological grounding to patterns families sometimes already notice.
Neurodevelopmental awareness. The brain pathways implicated — axonal transport, chromatin remodeling, MHC-region neuroinflammation — are active across the full arc of neurodevelopment, from prenatal periods through adolescence. Environmental factors interacting with these pathways (prenatal infection, gestational stress, early-life adversity) are studied risk modifiers.
Stigma and framing. Both ASD and schizophrenia have historically been the subject of stigmatizing narratives. The genetic science makes clear that these are neurodevelopmental and psychiatric conditions with biological roots — not choices, failures of willpower, or reflections of character. A result in this trait category should reinforce that framing.
The distinction between the two conditions remains clinically meaningful. ASD primarily involves differences in social communication and sensory processing, often present from early childhood, and is not a psychotic condition. Schizophrenia involves positive symptoms (hallucinations, delusions), negative symptoms (social withdrawal, flattened affect), and cognitive changes, typically emerging in late teens or early twenties. Shared genetic risk does not blur these clinical realities.
Working with your Autism & Schizophrenia Shared Risk result
If your result in this category is elevated, consider these evidence-grounded steps — in order of general priority:
Contextualize with family history. Note whether any first- or second-degree relatives have received a clinical assessment for ASD, schizophrenia, schizoaffective disorder, or related conditions. Family history remains one of the strongest known risk factors for both, and it provides meaningful context alongside a genetic result.
Prioritize neurodevelopmental monitoring for children. For those with children or planning families, awareness of early developmental milestones — language acquisition, social responsiveness, eye contact, and sensory processing — supports timely referral if concerns arise. Early intervention for ASD is highly effective and is one of the most evidence-supported recommendations in pediatric developmental medicine.
Recognize adolescent mental health warning signs. Schizophrenia typically emerges between ages 16 and 25. Early warning signs can include gradual social withdrawal, declining academic or occupational functioning, unusual or disorganized thinking, and changes in sleep or perception. Earlier engagement with mental health care during this prodromal period is associated with better outcomes.
Manage environmental risk modifiers. Chronic stress, cannabis use (particularly high-potency products in adolescence), sleep disruption, and social isolation are all studied environmental risk amplifiers for psychosis in genetically susceptible individuals. Sleep hygiene and stress regulation are modifiable and low-risk starting points.
Build support networks and reduce isolation. Community support, peer networks, and family education improve outcomes for both ASD and schizophrenia. Reducing isolation is protective. Organizations including the Autism Society of America and the National Alliance on Mental Illness (NAMI) provide both information and community connection.
Consult a clinical geneticist or psychiatrist if concerned. A genetic result in a wellness context is a starting point, not a clinical assessment. A psychiatrist or clinical geneticist can contextualize polygenic risk data alongside family history, developmental history, and clinical observation.
Related traits and genes
Autism & Schizophrenia Shared Risk sits within a broader cluster of neurodevelopmental and psychiatric genetics traits available on ExomeDNA. Related areas include:
- Neurodevelopmental traits — cognitive function, educational attainment, and working memory all share partial genetic overlap with ASD and schizophrenia GWAS signals.
- Psychiatric cross-disorder genetics — bipolar disorder, major depressive disorder, and ADHD have documented genetic correlations with schizophrenia and ASD, reflecting shared neurodevelopmental pathways.
- MHC-region immune-brain traits — the 6p21 chromosomal region implicated via AGER and ABHD16A also harbors signals for inflammatory and autoimmune conditions, connecting psychiatric and immunological genetics.
Key genes from this trait to explore further: AGER (MHC class III region, neuroinflammation), ACTR1A (dynactin complex, axonal transport), and ACTR5 (chromatin remodeling, neurodevelopmental epigenetics).
Frequently asked questions
See the FAQ schema section below for structured markup.
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.